Eli Lilly and Company

LLY

US5324571083

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 14/09/2024 am IST			5-day change	1st Jan Change
923.71 ^USD	-1.21%		+2.33%	+58.46%

13/09	Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss	DJ
13/09	Eli Lilly Gets US FDA Approval for Atopic Dermatitis Treatment	MT

Eli Lilly raises annual profit forecast as Zepbound quarterly sales cross $1 billion

August 08, 2024 at 04:20 pm IST

(Reuters) - Eli Lilly on Thursday raised its annual profit forecast and sales of its popular weight-loss drug Zepbound crossed $1 billion for the first time in a quarter.

The drugmaker now expects adjusted profit of $16.10 to $16.60 per share for 2024, compared with prior forecast of $13.50 to $14.

(Reporting by Bhanvi Satija and Sriparna Roy in Bengaluru and Patrick Wingrove in New York; Editing by Sriraj Kalluvila)

Stocks mentioned in the article

	Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	ELI LILLY AND COMPANY	923.71 USD	-1.21%	+2.33%	83TCr
	NOVO NORDISK A/S	918.50 DKK	+0.47%	+4.20%	60TCr

Latest news about Eli Lilly and Company

Eli Lilly Gets FDA Approval for Eczema Treatment Ebglyss	14/09	DJ
Eli Lilly Gets US FDA Approval for Atopic Dermatitis Treatment	14/09	MT
FDA Approves Lilly's EBGLYSS (Lebrikizumab-Lbkz) for Adults and Children 12 Years and Older with Moderate-To-Severe Atopic Dermatitis	14/09	CI
Correction to Eli Lilly Gets FDA Approval for Eczema Treatment Article	14/09	DJ
A central bank and it's off again?	13/09
JPMorgan Raises Price Target on Eli Lilly to $1,100 From $1,050	13/09	MT
Eli Lilly to Expand Two Ireland Sites With $1.8 Billion Investment	13/09	MT
Eli Lilly invests $1.8 billion in Ireland sites to scale up Alzheimer's, obesity drug production	13/09	RE
Sector Update: Health Care Stocks Rise in Thursday Trading	13/09	MT
Sector Update: Health Care	13/09	MT
Top Midday Stories: Moderna Shares Tumble on R&D Expense Cuts; Mastercard to Buy Recorded Future for $2.65 Billion	12/09	MT
Eli Lilly Investing Additional $1 Billion in Ireland Manufacturing Plant	12/09	DJ
ECB to cut rates without lowering its guard	12/09
Eli Lilly: invests $1.8 billion in two sites in Ireland	12/09	CF
Eli Lilly Invests $1.8 Billion in Ireland Site Expansions	12/09	MT
Roche shares drop on side effects result in early-stage obesity pill trial	12/09	RE
Arctoris Limited acquired the majority of the Life Sciences Studio laboratory of Eli Lilly Company (NYSE: LLY).	12/09	CI
Eli Lilly: phase 3 trials on weekly insulin	11/09	CF
Health Care Up on Defensive Bias -- Health Care Roundup	11/09	DJ
Weight-loss market to see 16 new drugs by 2029, report estimates	11/09	RE
Eli Lilly Says Efsitora Effective in Adults With Type 1 or 2 Diabetes in Phase 3 Trials	10/09	MT
Nanosyrinx Ltd. announced that it has received £10 million in funding from BGF Investment Management Ltd., Merck Ventures B.V., Octopus Ventures Ltd., Eli Lilly and Company, IQ Capital Partners LLP, Meltwind Advisory	10/09	CI
Lilly appoints insider as finance chief amid rising investments to boost capacity	10/09	RE
The market burns its idols	09/09
Eli Lilly Appoints New Finance Chief	09/09	MT

Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows: - endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems; - oncology (19.5%); - immunology diseases (11.1%); - neurology (8.4%): primarily drugs used in treating depression and schizophrenia; - other (3.3%). Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).

Employees

43,000

Sector

Pharmaceuticals

Calendar

30/10/2024 - Q3 2024 Earnings Release

More about the company